Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows - 2As world leaders enter climate talks, people in poverty have the most at stake
- 3Instructions to Pick the Right Toothpaste for Your Dental Requirements
- 4Reactions as Artemis II astronauts lift off on historic lunar mission
- 5Posts falsely claim Malaysian minister to relocate public hospital for temple
- Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
- Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
- Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- The Green Transformation: 5 Feasible Living Practices
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- 41 Young Men Die in South Africa After Circumcision Initiation
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
